Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study
European Journal of Neurology · 2025-06 · 32 (6)
DOI: 10.1111/ene.70262 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 25.06.2025. Verfasst von Gregorio Spagni und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Myasthenia Gravis, Patient Reported Outcome Measures. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, the Myasthenia Gravis Rare Disease Network-MGNet, NIHR Academic Clinical Lectureship.
Abstract (Originalsprache)
Introduction
Patient Acceptable Symptom State (PASS) is emerging as a valuable subjective measure of the overall myasthenia gravis (MG)‐related burden. This study aimed at identifying PASS‐positive thresholds for the most used clinical scales, investigating whether PASS and MGFA post‐intervention status capture different aspects of the disease outcome, and identifying clinical variables associated with PASS=YES response.
Methods
Adult AChR‐MG patients were prospectively enrolled at two Italian Centres (Rome: index cohort; Florence: validation cohort). PASS thresholds for MG‐ADL, QMG, and MG‐QOL15r were defined in the index cohort by ROC analysis and validated in the validation cohort; predictors of favorable PASS were identified by multivariable analysis.
Results
This study included 173 patients (44% females, median age at onset: 53 years). PASS=YES patients had significantly lower median MG‐ADL, QMG, and MG‐QOL15r scores, with the following thresholds for PASS=YES: MG ADL ≤ 2, QMG ≤ 8 and MG‐QOL15r ≤ 6. The MG‐ADL (OR = 0.46, 95% CI = 0.36–0.60, p < 0.001), QMG (OR = 0.72, 95% CI = 0.64–0.81, p < 0.001) and MG‐QOL15r (OR = 0.76, 95% CI = 0.70–0.84, p < 0.001), were independently associated with a favorable PASS. The degree of ocular involvement in each scale was the strongest negative determinant of PASS=YES.
Conclusions
This study validates the PASS question and highlights the relevance of ocular complaints in patients' perception of MG burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
- Department of Neurosciences and Sensory Organs, Careggi University Hospital, Florence, Italy.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
- Department of Neurosciences, Catholic University of the Sacred Hearth, Rome, Italy.
ORCID-Profile: Gregorio Spagni, Amelia Evoli
Förderung
- NCATS NIH HHS
- the Myasthenia Gravis Rare Disease Network-MGNet
- NIHR Academic Clinical Lectureship
- Ministero dell'Istruzione, dell'Università e della Ricerca
- Italian Ministry of Health
- NINDS NIH HHS
- Ministero della Salute
Zitieren
APA
Spagni, G., Verza, M. U., Cornacchini, S., Beretta, F., Sun, B., Lotti, A., Falso, S., Barilaro, A., Massacesi, L., Evoli, A., & Damato, V. (2025). Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study. European Journal of Neurology, 32(6). https://doi.org/10.1111/ene.70262
Vancouver
Spagni G, Verza MU, Cornacchini S, Beretta F, Sun B, Lotti A, et al. Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study. European Journal of Neurology. 2025;32(6). doi:10.1111/ene.70262
BibTeX
@article{Spagni2025,
author = {Spagni, Gregorio and Verza, Massimiliano Ugo and Cornacchini, Sara and Beretta, Francesca and Sun, Bo and Lotti, Antonio and Falso, Silvia and Barilaro, Alessandro and Massacesi, Luca and Evoli, Amelia and Damato, Valentina},
title = {Validation of the “Patient‐Acceptable Symptom State” Question as Outcome Measure in AChR Myasthenia Gravis: A Multicentre, Prospective Study},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {6},
doi = {10.1111/ene.70262}
}
EUVIMED